# Trial of NanoPac Intratumoral Injection in Lung Cancer

> **NCT04314895** · PHASE2 · COMPLETED · sponsor: **NanOlogy, LLC** · enrollment: 18 (actual)

## Conditions studied

- Lung Cancer, Nonsmall Cell
- Lung Cancer
- Lung Cancer, Small Cell
- Neoplasm of Lung

## Interventions

- **DRUG:** NanoPac (sterile nanoparticulate paclitaxel) Powder for Suspension

## Key facts

- **NCT ID:** NCT04314895
- **Lead sponsor:** NanOlogy, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-14
- **Primary completion:** 2023-09-26
- **Final completion:** 2023-09-26
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2025-05-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04314895

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04314895, "Trial of NanoPac Intratumoral Injection in Lung Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04314895. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*